Your browser doesn't support javascript.
loading
Successful liver transplantation as rescue therapy in a patient with metastases from a vasoactive intestinal peptide producing neuroendocrine tumor.
Andreassen, Mikkel; Garbyal, Rajendra Singh; Larsen, Peter Nørgaard; Hansen, Carsten Palnæs; Hannibal, Jens; Oturai, Peter; Knigge, Ulrich; Schultz, Nicolai.
Afiliação
  • Andreassen M; ENETS Center of Excellence, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Garbyal RS; Department of Endocrinology and Metabolism, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Larsen PN; ENETS Center of Excellence, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Hansen CP; Department of Pathology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Hannibal J; ENETS Center of Excellence, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Oturai P; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Knigge U; ENETS Center of Excellence, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Schultz N; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
J Surg Case Rep ; 2024(5): rjae371, 2024 May.
Article em En | MEDLINE | ID: mdl-38826856
ABSTRACT
This case report presents a 40-year-old patient with a vasoactive intestinal peptide (VIP) secreting high grade (Ki-67 39%) neuroendocrine tumor (NET) from the pancreas, for whom successful liver transplantation (LT) was carried out 8 years after resection of the primary tumor due to massive liver metastases. The transplantation was done as rescue therapy due to rapid progression and a devastating clinical condition requiring intravenous supplementation for 20 hours daily. The latest imaging carried out 18 months after transplantation is without signs of recurrence, and the patient is in good health with undetectable levels of VIP. According to the guidelines, LT is only recommended if Ki-67 is <20% and if there has been tumor control for more than 6 months prior to transplantation. Our case illustrates that LT is an option that should be considered for selected NET patients without extrahepatic involvement regardless of tumor grade and clinical condition.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article